Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology

Dr Toni Choueiri, Dr Andrea Apolo, Dr Neeraj Agarwal, Dr Piet Ost, Dr Sean...

OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology ( Dr Toni Choueiri, Dr Andrea Apolo, Dr Neeraj Agarwal, Dr Piet Ost, Dr Sean McBride, Dr Ravindran Kanesvaran & Dr Nicolo Battisti )

Dihydropyrimidine dehydrogenase polymorphisms knocking on the door

Dr Mauro Daniel Donadio - AC Camargo Cancer Center, Sao Paulo, Brazil

Dihydropyrimidine dehydrogenase polymorphisms knocking on the door ( Dr Mauro Daniel Donadio - AC Camargo Cancer Center, Sao Paulo, Brazil )

Frontline treatment with single agent pembrolizumab followed by AVD...

Prof Pamela Allen - Emory University School of Medicine, Georgia, USA

Frontline treatment with single agent pembrolizumab followed by AVD chemotherapy for classic Hodgkin lymphoma ( Prof Pamela Allen - Emory University School of Medicine, Georgia, USA )

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC

Dr Aditya Bardia - Mass General Cancer Center, Boston, USA

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer...

Dr Sara Hurvitz - University of California, Los Angeles, USA

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups ( Dr Sara Hurvitz - University of California, Los Angeles, USA )

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib +...

Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease ( Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA )

Efficacy and safety of selinexor in patients with myelofibrosis refractory or...

Prof Srinivas Tantravahi - University of Utah, Salt Lake City, USA

$Efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors ( Prof Srinivas Tantravahi - University of Utah, Salt Lake City, USA )$

Significance of gut microbiota in patients receiving CAR T cell immunotherapy

Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA

Significance of gut microbiota in patients receiving CAR T cell immunotherapy ( Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA )

Cancer medicine shortages for children around the world

Dr Carlos Rodriguez-Galindo - St. Jude Children’s Research Hospital, Memphis...

Cancer medicine shortages for children around the world ( Dr Carlos Rodriguez-Galindo - St. Jude Children’s Research Hospital, Memphis, USA )

INTEGRATE study: Treatment pathways, outcomes and resource use in patients with...

Prof Meral Beksac and Prof Roman Hájek

INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma ( Prof Meral Beksac and Prof Roman Hájek )

Tisagenlecleucel shows no EFS improvement on standard of care in 2L for...

Dr Michael Bishop - University of Chicago, Chicago, USA

Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL ( Dr Michael Bishop - University of Chicago, Chicago, USA )

Asciminib found to be safe and effective for heavily pretreated patients with...

Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA

Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase ( Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA )

More from ecancer